Novartis AG ADR (NVS)vsSera Prognostics Inc (SERA)
NVS
Novartis AG ADR
$140.79
+1.77%
HEALTHCARE · Cap: $267.60B
SERA
Sera Prognostics Inc
$2.07
+0.98%
HEALTHCARE · Cap: $78.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 80989897% more annual revenue ($56.69B vs $70,000). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SERA
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.2%
Fair Value
$93.54
Current Price
$140.79
$47.25 premium
Margin of Safety
-73.8%
Fair Value
$1.49
Current Price
$2.07
$0.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 76.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SERA
The strongest argument for SERA centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 76.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while SERA is a hypergrowth play — different risk/reward profiles.
SERA carries more volatility with a beta of 1.06 — expect wider price swings.
SERA is growing revenue faster at 76.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 35/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a pioneering force in maternal-fetal health, focusing on cutting-edge diagnostic solutions designed to enhance pregnancy outcomes. Its flagship product, the PreTRM test, harnesses a unique biomarker platform to accurately evaluate the risk of preterm birth, enabling healthcare providers to implement timely and impactful interventions. With a steadfast commitment to advancing prenatal diagnostics and addressing pivotal health challenges, Sera is strategically positioned for significant growth within the maternal health sector, offering investors compelling opportunities for long-term value creation.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?